about
Weight loss dynamics during combined fluoxetine and olanzapine treatmentExcessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.Weight gain, obesity, and psychotropic prescribing.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.The relationship between obesity and psychiatric disorders across ethnic and racial minority groups in the United States.Children with special health care needs: acknowledging the dilemma of difference in policy responses to obesity.Interventions for body weight reduction in obese patients during short consultations: an open-label randomized controlled trial in the Japanese primary care setting.Inequitable access for mentally ill patients to some medically necessary proceduresBody Image in Adult Women: Moving Beyond the Younger Years.A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.Psychiatric medication-induced obesity: a review.The Metabolic Syndrome in Patients With Severe Mental IllnessesReducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study.Bipolar disorder in women: reproductive events and treatment considerations.The impact of European regulatory policies on psychotropic drug prescribing patterns.Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring.Correlates of weight gain during long-term risperidone treatment in children and adolescentsTopiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.What does the epidemic of childhood obesity mean for children with special health care needs?Clinical and neurophysiological study of peroneal nerve mononeuropathy after substantial weight loss in patients suffering from major depressive and schizophrenic disorder: Suggestions on patients' management.Prevalence and correlates of eating disorder co-morbidity in patients with bipolar disorder.Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Schizophrenia, obesity, and antipsychotic medications: what can we do?Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.BIDIRECTIONAL PROSPECTIVE ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH DEPRESSION, ANXIETY, AND ANTIDEPRESSANT USE.Sex Differences in the Physiological and Behavioral Effects of Chronic Oral Methylphenidate Treatment in RatsObesity and psychotropics.Weight changes and characteristics of patients associated with weight gain during inpatient psychiatric treatment.A systematic review of controlled interventions to reduce overweight and obesity in people with schizophrenia.Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.Effectiveness of a Staff Promoted Wellness Program to Improve Health in Residents of a Mental Health Long-Term Care Facility.Ameliorative Effect of Curcumin on Olanzapine-induced Obesity in Sprague-Dawley Rats.Putting desire on a budget: dopamine and energy expenditure, reconciling reward and resources.How can research ethics committees protect patients better?The long-term effect of acupuncture for patients with chronic tension-type headache: study protocol for a randomized controlled trial.Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis.Phase II trial of mirtazapine for cancer-related cachexia and anorexia.Investigation of antidepressant medication usage after bariatric surgery.
P2860
Q24794172-0772916C-0C74-42FD-980F-D8631067798EQ33256430-F1D0FBD9-A648-429A-869F-20C6B9D9A8C6Q34056408-E3F5993F-95A2-4920-8C21-7DC69F758BE8Q34557537-6F905883-8DA1-4F07-96A1-0F93CBF8E824Q34623350-71A64A90-DB27-4842-ADD1-8D00A58D9C34Q34644304-91670B27-F461-44D4-AAA8-E9FD683DB24BQ35235190-D01C2975-D0FA-4B26-AEB5-142F05C63358Q35646144-4C82B780-E77A-45A1-9D3D-5D165EF55AD5Q35659782-5064E7CC-FED4-493B-A5B4-9E8226A8EB06Q35674109-5DAAFC6E-71BE-4BE5-B7E1-ADCC4AC2398BQ35709161-1A70AD52-BB63-48FD-BD41-E4A06B31212AQ35746806-86671EEC-6232-4B91-8106-B92BA6680EEBQ35884715-683F6DEA-7DCB-4C9D-A516-B0DFA1808FC0Q35906535-DBE31227-9A77-4B3B-89F4-0F2FFDED4950Q36181505-7D159840-AA2D-47D6-A6FC-993B461943D5Q36272515-1B7A505F-E592-4E5C-BB0C-3DE46E3EDCCDQ36302677-5D76576B-F7C9-41BD-8CBD-4A532BE5EB7AQ36373562-194B4CF3-6FE5-4A08-9939-9375D76053BAQ36414182-A9ECC434-85FF-41F9-8734-BA0442CAEE23Q36651127-4F202242-BB5B-4B89-B957-811ED135828AQ37008379-7EBEB6FD-FCAF-48CD-9DFE-518AD119B540Q37098549-5D5D3CFE-8C78-4CFE-A11E-3435037399CFQ37144258-5940EB62-55DA-40CD-ACCE-AA7F6793FB6AQ37160453-038CC303-BF9F-4D74-B429-B2AA3DCA9378Q37226376-71BF7489-230B-442B-95A6-2899DD109EE8Q37273061-4329E458-D178-41AB-BCD1-01765DD1F9F2Q37418039-1F1C6FBC-08C9-47BF-BA68-2C417690D474Q37723437-3B4EB248-B1DC-460E-8D41-C00C069F27ADQ37954390-66E79A20-26FD-4804-8B95-B7D59ADFBA78Q38031006-2E777615-06FB-4C54-A252-8555A45799ACQ38179063-045EA416-0E01-415B-8507-B1C5D875B376Q38677949-1268EDE1-E383-4487-86B7-AB4BB01DF530Q39875218-B72E5F68-D4A3-4250-9582-542A3AB1C3B7Q41226651-6F6884E4-703B-4B39-9637-DEED72EBA019Q41870037-B1F6FAF8-11AD-4478-8792-BAD74DDBB566Q42084184-E416FBB0-BE0E-40FE-A1E3-9B96E1C69D64Q42281177-CB63054A-1CF7-4D19-B2FC-0EE4AD02C134Q42831163-76C6939F-70A0-4E19-B8C9-51EDC18A856CQ43272312-6A9E39BD-5BAE-4837-9604-79CB4721DC16Q44176317-058AB0A3-FB6A-43E3-A3CC-6C6284498BD1
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Body weight changes associated with psychopharmacology.
@ast
Body weight changes associated with psychopharmacology.
@en
Body weight changes associated with psychopharmacology.
@nl
type
label
Body weight changes associated with psychopharmacology.
@ast
Body weight changes associated with psychopharmacology.
@en
Body weight changes associated with psychopharmacology.
@nl
prefLabel
Body weight changes associated with psychopharmacology.
@ast
Body weight changes associated with psychopharmacology.
@en
Body weight changes associated with psychopharmacology.
@nl
P2093
P356
P1433
P1476
Body weight changes associated with psychopharmacology.
@en
P2093
Abufarah Siddiqui
Anna Podolskaya
Firoz Munshi
Hasan Shahab
Karim Sedky
Steven Lippmann
Yelena Vanina
P304
P356
10.1176/APPI.PS.53.7.842
P577
2002-07-01T00:00:00Z